Control of lipolysis in intra-abdominal fat cells of nonhuman primates: comparison with humans.
The mechanisms that control lipolysis in intra-abdominal fat cells from various primate species, the marmoset (Callithrix jacchus), the baboon (Papio papio), and the macaque (Macaca fascicularis), were compared to those of human intraabdominal fat cells. Selective beta 1- or beta 2-adrenoceptor agonists induced lipolysis in all species. Selective beta 3-agonists (BRL 37344, CL 316243, and SR 58611) acted as partial agonists in marmoset but were inefficient in other primates, including humans. alpha 2-Adrenoceptor number ([3H]RX 8210002 binding) equalized (baboon) or exceeded (other primates) beta 1/beta 2-adrenoceptors ([3H]CGP 12177 binding). Baboon fat cell membranes expressed similar amounts of coupled beta- and alpha 2-adrenoceptors. In all species, norepinephrine- or epinephrine-induced lipolysis did not reach the lipolytic effect of isoproterenol but their effects were enhanced after alpha 2-adrenoceptor blockade. N6-phenylisopropyladenosine (PIA) induced a full antilipolytic effect in baboon, macaque, and human adipocytes through adenosine receptors ([3H]DPCPX binding). Peptide YY (PYY) weakly inhibited lipolysis in baboon. Adrenocorticotropic hormone (ACTH) was inactive whereas parathyroid hormone (PTH) partially stimulated lipolysis in primates. Histamine was partially lipolytic in marmoset only. This study emphasizes the similarities of the mechanisms controlling the lipolysis in nonhuman primate and in human adipocytes and suggests that the baboon and the macaque should provide unique models for the study of the regulation of lipolysis.
Bousquet-Mélou
A
A
Institut National de la Santé et de la Recherche Médicale (INSERM), Faculté de Médecine, Toulouse, France.
Galitzky
J
J
Lafontan
M
M
Berlan
M
M
D000005:Abdomen; D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism*; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000368:Aged; D000818:Animals; D000068438:Brimonidine Tartrate; D003994:Bucladesine / Q000494:pharmacology; D002144:Callithrix; D005576:Colforsin / Q000494:pharmacology; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008066:Lipolysis / Q000187:drug effects / Q000502:physiology*; D008252:Macaca fascicularis; D008297:Male; D008875:Middle Aged; D010215:Papio; D019894:Peptide YY; D010455:Peptides / Q000494:pharmacology; D011323:Primates / Q000378:metabolism*; D011810:Quinoxalines / Q000494:pharmacology; D011942:Receptors, Adrenergic, alpha / Q000378:metabolism; D011943:Receptors, Adrenergic, beta / Q000378:metabolism; D018047:Receptors, Purinergic P1 / Q000378:metabolism; D013045:Species Specificity
D000316:Adrenergic alpha-Agonists; D000318:Adrenergic beta-Agonists; D010455:Peptides; D011810:Quinoxalines; D011942:Receptors, Adrenergic, alpha; D011943:Receptors, Adrenergic, beta; D018047:Receptors, Purinergic P1; D019894:Peptide YY; D005576:Colforsin; D000068438:Brimonidine Tartrate; D003994:Bucladesine; D000324:Adrenocorticotropic Hormone